UK Biobank

Lead Research Organisation: UK Biobank

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. By 2015, there will start to be sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants (although research related to conditions present at baseline has already started).
Hence, the chief emphasis for the past 5 years has been on preparing UK Biobank for effective use as a prospective resource by the widest possible range of researchers. This activity has included: developing resource access management systems; conducting repeat assessments in 20,000 participants; establishing record linkage for death, cancer and hospitalisation; piloting large-scale characterisation of commoner conditions; enhancing participant phenotyping; preparing for imaging assessments; and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to: review and streamline further the access systems; extend record linkage to primary care records and conduct direct participant follow-up (e.g. for cognitive function); implement large-scale characterisation of commoner conditions; pilot the imaging assessments and move forward to the main phase of imaging in 100,000 participants; make available genotypic and biomarker data for all 500,000 participants. Efforts will also be made to ensure that researchers from around the world are suitably well informed about these developments so that use of the resource increases substantially over the next few years.

Publications

10 25 50
 
Description Extension to UK Biobank
Amount £7,000,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 11/2010 
End 11/2015
 
Title UK Biobank resource 
Description A collection of baseline data, physical measures and biological samples from 500,000 members of the UK public aged between 40 and 69 years was made available for researchers to access in 2012. The biological samples are being processed to generate genetic data and biomarker data for all 500,000 study participants. Data on approx. 820,000 SNPs from across the genome will incorporated into the Resource and made publically available during 2015, together with a wide range of biomarkers, chosen to provide an accurate indication of participants' risks of developing a variety of health conditions. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2012 
Provided To Others? Yes  
Impact The resource is open-access, meaning it is available to bona fide researchers from across the world to conduct research that is deemed to be in the public interest. This has led to significant contributions to knowledge of how to build very large research resources. It has also pushed policy on ethics and governance, research access and feedback of findings from measurements of volunteers. 
URL http://www.ukbiobank.ac.uk
 
Title UK Biobank sample archive 
Description The UK Biobank baseline recruitment has generated 15 million biological sample. These are stored in a state of the art sample processing and archiving facility in South Manchester. Samples are retrieved at a maximum rate of 1500 samples per day to extract DNA (for genotyping) and to assay biomarkers for all 500,000 study participants. 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact The knowledge and infrastructure involved in developing the sample resource is available to other research groups 
 
Description Biobank Enhancement 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution exome sequencing of 50,000 participants
Collaborator Contribution creating vast amounts of genetic data to be used by researchers accessing UKBiobank
Impact exome data
Start Year 2017
 
Description Biobank Enhancement 
Organisation Regeneron Pharmaceuticals, Inc.
Country United States 
Sector Private 
PI Contribution exome sequencing of 50,000 participants
Collaborator Contribution creating vast amounts of genetic data to be used by researchers accessing UKBiobank
Impact exome data
Start Year 2017
 
Description Dementia Platform UK 
Organisation MRC Dementias Platform UK
Country United Kingdom 
Sector Public 
PI Contribution development of cognitive function tests
Collaborator Contribution development of cognitive function tests
Impact n/a
Start Year 2014
 
Description Farr Institute of Health Informatics Research 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution partner for data analysis
Collaborator Contribution partner for data analysis
Impact n/a
Start Year 2011
 
Description Genetic enhancement 
Organisation AbbVie Inc
Country Global 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Alnylam Pharmaceuticals
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Biogen Idec
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Bristol-Myers Squibb
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Pfizer Inc
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Regeneron Pharmaceuticals, Inc.
Country United States 
Sector Private 
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description Genetic enhancement 
Organisation Takeda Pharmaceutical Company
Department Takeda Pharmaceuticals U.S.A., Inc. (TPUSA)
PI Contribution Partnership with Regeneron and GSK to complete exome sequencing of 450,000 UKBiobank participants
Collaborator Contribution The exome sequence of 50,000 UKBiobank particpants were generated through a partnership between UKB, Regeneron and GSK. Regeneron is leading a consortium of biopharma (listed) to complete exome sequencing of the remaining 450,000 participants by 2020. GSK has committed an additional £40 million investment to initiatives, such as UKB, that harness advances in genetic research in the development of new medicines.
Impact The first tranche of data have been incorporated back into the UKBiobank resource for the global health community to use.
Start Year 2018
 
Description German Cancer Research Centre 
Organisation German Cancer Research Center
Country Germany 
Sector Public 
PI Contribution development of infectious disease assay panel
Collaborator Contribution development of infectious disease assay panel
Impact n/a
Start Year 2014
 
Description Imperial College London 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution development of occupational health webQ
Collaborator Contribution development of occupational health webQ
Impact development of occupational health webQ
Start Year 2014
 
Description NIH Precision Medicine Initiative 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution Member of steering committee
Collaborator Contribution Taking forward US precision medicine programme
Impact N/A
Start Year 2015
 
Description WTCHG 
Organisation University of Oxford
Department Oxford Genomics Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution development of processing of genotyping data
Collaborator Contribution development of processing of genotyping data
Impact development of processing of genotyping data
Start Year 2014
 
Title Automated -80C archive 
Description Automated system for the storage and accurate retrieval of 10 million biological samples at -80C Also published as EP1639892 
IP Reference US2006053825 
Protection Patent application published
Year Protection Granted 2006
Licensed Yes
Impact None
 
Title Automated blood processing platforms 
Description High throughput automation for procesing blood - developed with a local company. Given our intellecdtual input, we have agreed a revenue sharing deal with them. 
IP Reference WO2006037941 
Protection Patent application published
Year Protection Granted 2006
Licensed Yes
Impact None
 
Company Name UK Biocentre 
Description Provision of services to academic and commercial collaborators conducting studies involving human volunteers. Services are principally sample collection, processing, archiving and assay 
Year Established 2011 
Impact First agreements in place - providing sample curation and archiving and processing of research samples collected from a clinical trial to Leukameia and Lymphoma Research
Website http://www.ukbiocentre.com/
 
Description UK Biobank Annual Scientific Symposium 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact Each year UK Biobank organises their annul scientific symposium for partcipants, scientists and funders. These events are used to inform participants about the work of the Biobank, and as a tool to encourage scientists to take part.
Year(s) Of Engagement Activity 2014,2015,2016,2017
URL http://www.ukbiobank.ac.uk
 
Description UK Biobank Scientific Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London
Year(s) Of Engagement Activity 2018
 
Description UK Biobank public meetings 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Inform participants of UKB and the way information is being used and to learn how they want the resource to develop. It resulted in requests for further information and taking part in enhancement studies. Presentations have taken place across the UK (and continue to do so):
Edinburgh Nov 14 - 150 people
Edinburgh Jan 15 - 300 people
Manchester 4 events x 200 people at each 18 march, 22 april, 28 may, 22 september
Nottingham 1 event - 200 people 12 nov 16
Leeds 1 event - 200 people 1 march 2016
Year(s) Of Engagement Activity 2014,2015,2016
 
Description UKBiobank participant events - 2014 - 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2019 over 3,000 participants have taken part in events in Edinburgh (2), Manchester (4), Nottingham, Leeds, Cardiff, Newcastle (4), Glasgow (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing)
Year(s) Of Engagement Activity 2014,2015,2016,2017,2018
URL http://www.ukbiobank.ac.uk